ImmunoScape wins Emerging Enterprise Award 2020

December 11, 2020

ImmunoScape won Singapore’s most prestigious Emerging Enterprise Award organized by Business Times and OCBC Bank. Emerging Enterprise Award honors the bold ambition of Singapore’s young businesses. It is a celebration of business innovation, resilience and excellence in SMEs. The award is for “demonstrating an enterprising mindset and displaying potential for significant and sustainable growth”. Click here […]

MGH Collaboration

October 20, 2020

In the fight against COVID-19, ImmunoScape is joining forces with Dr. Patrick Reeves, Team Leader at the Massachusetts General Hospital Vaccine & Immunotherapy Center, using its signature assay, TargetScape, to perform high-dimensional immune profiling of COVID-19 induced changes across immune populations and phenotypes with a focus on antigen-specific T cells. The study will investigate the […]

Arcturus Collaboration

August 20, 2020

As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and prevention of diseases with high unmet medical needs, and Duke-NUS, who will be running the clinical trial in healthy subjects in Singapore. The Arcturus LUNAR-COV19 vaccine, which uses Arcturus proprietary STARR™ and LUNAR® technologies is […]

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC

August 11, 2020

The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology Using T-Cell Immune Response Profiling Platform

August 9, 2020

ImmunoScape studying immune response to Covid-19

May 21, 2020

The Straits Times recently interviewed ImmunoScape executives to learn about their current global collaborations to help understand the immune response to Covid-19 and how they can aid vaccine development. 

ImmunoScape and LaJolla

ImmunoScape at LJI

February 11, 2020

ImmunoScape has established an on-site presence at La Jolla Institute of Immunology to support the research needs of their scientists. ImmunoScape provides high dimensional immune profiling using mass cytometry and their proprietary know-how, including tetramer multiplexing technology.

MGH Collaboration

January 22, 2020

Dr Patrick Reeves at the Massachusetts General Hospital is collaborating with ImmunoScape on a pilot study to evaluate flu-specific T cell responses induced in participants taking part in a clinical trial of FluGen’s novel M2SR influenza vaccine using mass cytometry.

ImmunoScape and UCSF Collaboration

UCSF Collaboration

December 17, 2019

Prof. Hideho Okada at the University of California San Francisco is collaborating with ImmunoScape on a study to evaluate the vaccine-specific T cell response induced by a rationally designed vaccine administered to a targeted group of patients with WHO grade II glioma, a form of brain cancer that often progresses into an aggressive high-grade glioma, […]